MSA has an estimated prevalence between 0.5 to 7.0 cases per 100,000 people. It typically strikes in late middle age, with a mean age of onset around 50-60 years. Men and women are affected about equally. The relative frequency of MSA subtypes may vary geographically, with the parkinsonian MSA-P subtype being more common in Europe and North America, and the cerebellar MSA-C subtype being more frequent in Asian populations.

The exact cause of MSA is unknown. It is generally considered a sporadic disease without a clearly identifiable inherited pattern. The misfolding and aggregation of α-synuclein into intracellular inclusions in glial cells is a hallmark feature. Unlike Parkinson’s disease, where α-synuclein aggregates within neurons, in MSA the aggregates form inside cells that are responsible for making myelin that insulates and supports nerve fibers, leading to cell death and damage to nerve networks. The possible role of environmental factors in MSA causation is under investigation.

Symptoms are broadly divided into motor and non-motor/autonomic categories. Patients are often subtyped based on their predominant motor symptoms:

• MSA-P (Parkinsonian variant): Features symmetrical bradykinesia (slowness of movement), muscle rigidity, tremor, speech impairment, postural instability, and weak responsiveness to the Parkinson’s drug levodopa.

• MSA-C (Cerebellar variant): Features gait and limb ataxia (uncoordinated movements), cerebellar dysarthria (slurred, explosive speech), and oculomotor abnormalities.

• Autonomic Dysfunction (present in both): Severe autonomic failure is typically required for clinical diagnosis. This usually manifests as neurogenic orthostatic hypotension (a significant drop in blood pressure upon standing, leading to fainting or lightheadedness) and urogenital dysfunction, including severe urinary urge incontinence, urinary retention, and erectile dysfunction. REM (rapid eye movement) sleep behavior disorder, constipation or bloating, and vocal cord paralysis (causing stridor or high-pitched breathing) are also very common.

Since early stage MSA overlaps with Parkinson’s disease and other atypical parkinsonisms, diagnosis is challenging. Diagnosis is typically based on clinical symptoms, neurologic examination, autonomic testing and exclusion of alternative synodromes. Tests may include:

• Clinical evaluation:  Adult-onset progressive disease, postural instability, urogenital problems, and high-pitched breathing. 

• MRI imaging:  Essential for identifying characteristic brain structural changes. Key markers include atrophy of the putamen, pons, or cerebellum, as well as specific signatures like the "hot cross bun" sign in the pons.

• Autonomic testing:  Tilt-table testing to confirm neurogenic orthostatic hypotension, reflex testing, and post-void ultrasound to check for urinary retention.

• Levodopa trial:  While patients with Parkinson's disease usually respond well to levodopa, patients with MSA typically have a poor, unsustained, or completely absent response.

Additional blood, metabolic or genetic testing may be done to exclude other conditions such as Parkinson’s, progressive supranuclear palsy, genetic ataxias, autoimmune disorders or drug-induced parkinsonism. A definitive diagnosis can be established after death by the demonstration of neurodegeneration with widespread α-synuclein-positive glial cytoplasmic inclusions.

There is no cure for MSA. Treatment involves a complex, multidisciplinary approach focused primarily on symptom management:

• Motor Symptoms:  Physical or occupational therapy, assistive devices, speech therapy, and a trial of levodopa is standard for MSA-P, though benefits are usually marginal.

• Autonomic Symptoms: Orthostatic hypotension is managed via lifestyle adjustments (hydration, salt intake, compression garments) and vasoactive medications like midodrine, fludrocortisone, or droxidopa. Urological interventions, such as anticholinergic drugs or intermittent catheterization, are used for bladder dysfunction. Erectile dysfunction may be treated with phosphodiesterase-5 inhibitors in appropriate patients. Dietary management and laxatives may be used to address constipation.

• Supportive Care: CPAP machines or tracheostomy may be required for severe sleep apnea or stridor. Physical, occupational and speech therapy are utilized to maintain patient safety, swallowing function, and mobility for as long as possible.

Advance-care planning is also important because MSA is progressive and can eventually impair mobility, communication, swallowing, bladder function, and respiratory function.

MSA is considered the most aggressive of the synucleinopathies. The disease progresses rapidly, typically leading to severe disability, wheelchair dependency, and significant speech and swallowing impairment within 5 to 6 years of symptom onset. The average survival time is between 6 and 10 years following symptom onset, with death most frequently resulting from aspiration pneumonia (food entering lungs), respiratory failure, or sudden cardiac events.

1. Goh, Y. Y., Saunders, E., Pavey, S., et al. 2023. “Multiple system atrophy.” Practical Neurology, 23, 208–221. https://doi.org/10.1136/pn-2020-002797.

2. Liu, M., Wang, Z., & Shang, H. 2024. “Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.” Journal of Neurology, 271, 2324–2344. https://doi.org/10.1007/s00415-024-12269-5.

3. Stefanova, N., & Wenning, G. K. 2016. “Review: Multiple system atrophy: emerging targets for interventional therapies.” Neuropathology and Applied Neurobiology, 42, 20–32. https://doi.org/10.1111/nan.12304.

4. Wenning, G. K., Stankovic, I., Vignatelli, L., et al. 2022. “The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. “Movement Disorders, 37, 1131–1148. https://doi.org/10.1002/mds.29005.

5. Orphanet:  Multiple system atrophy.

6. National Institute of Neurological Disorders and Stroke:  Multiple system atrophy.